Trial
NCT04837131
A Study to Evaluate the Safety and Tolerability of Oral Ixazomib in Scleroderma-related Lung Disease Patients
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Michael M. Pham
Collaborators
—
Condition
Systemic Sclerosis
Intervention
Ixazomib
Why stopped
Low enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-04-06